Sandoz, a Novartis division and the pioneer and global leader in biosimilars, has announced that the European Commission (EC) granted marketing authorization for biosimilar Ziextenzo (pegfilgrastim).
A unit of Johnson & Johnson has agreed to pay the U.S. government $360 million to resolve an investigation into its financial support of charities that help Medicare patients cover out-of-pocket drug costs, the U.S...
AstraZeneca announced positive results from the landmark phase III DAPA─HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically─significant and clinically─meaningful...
Want a balanced and actionable way to know if your content is doing what it’s supposed to do? Create a content scorecard. Here’s an easy-to-use format to evaluate your content quantitatively and qualitatively. Continue...
Brand Dashboard
PR- en digital marketingbureau Whizpr uit Wageningen introduceert een online dashboard dat real time inzicht geeft in de ontwikkelingen van een merk in online- en printmedia.
Findings from the phase 3 ASCLEPIOS I and II studies showed that treatment with ofatumumab (Novartis), a CD20-directed cytolytic monoclonal antibody, resulted in a highly significant and clinically meaningful reduction...
Monthly Prescribing Reference (MPR): Drugs in the Pipeline
Colonoscopy Your gut bacteria could say a lot about you, such as why you’re diabetic or how you respond to certain drugs.But scientists can see only so much of the gastrointestinal tract to study the role of gut...
Health minister invites Japanese pharma cos to collaborate with Indian firms for research and innovation Union minister of health and family welfare, Dr Mansukh Mandaviya has invited Japanese companies to collaborate...
Verzenio (abemaciclib) has been cleared by the EMA to treat women with hormone receptor-positive (HR+), epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer, as a first-line...
MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with metastatic squamous non-small cell lung cancer (NSCLC) when used...
We gebruiken cookies om ervoor te zorgen dat onze website zo soepel mogelijk draait. Als u doorgaat met het gebruiken van de website, gaan we er vanuit dat u ermee instemt.